Health
Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2) induces neutralising antibody and polyfunctional T‐cell responses in patients with chronic myeloid leukaemia – Wiley
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations,…
Introduction
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), a novel beta coronavirus, has led to unprecedented healthcare challenges on a global scale. Development of anti-viral immunity is key to reducing spread of infection and gaining pandemic control. Impressive collaborative efforts have led to the rapid development of multiple efficacious vaccines against SARS-CoV-2. BNT162b2 is a nucleoside-modified mRNA that encodes a full-length Spike that is stabilised in the pre-fusion…
-
General24 hours agoFire razes Tumby Bay hardware store with damage likely to exceed $1m
-
General24 hours agoDonald Trump and the ghost of Al Capone • Inside Story
-
Noosa News23 hours agoBrisbane’s covert cameras catching more than just litterbugs
-
General21 hours agoLiberals dump NSW candidate who said women should not serve in ADF combat